CA3095660A1 - Modified viral capsids - Google Patents
Modified viral capsids Download PDFInfo
- Publication number
- CA3095660A1 CA3095660A1 CA3095660A CA3095660A CA3095660A1 CA 3095660 A1 CA3095660 A1 CA 3095660A1 CA 3095660 A CA3095660 A CA 3095660A CA 3095660 A CA3095660 A CA 3095660A CA 3095660 A1 CA3095660 A1 CA 3095660A1
- Authority
- CA
- Canada
- Prior art keywords
- viral
- seq
- candidate
- modified
- capsid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18156932 | 2018-02-15 | ||
| EP18156932.8 | 2018-02-15 | ||
| PCT/EP2019/053610 WO2019158619A1 (en) | 2018-02-15 | 2019-02-14 | Modified viral capsids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3095660A1 true CA3095660A1 (en) | 2019-08-22 |
Family
ID=61521290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3095660A Pending CA3095660A1 (en) | 2018-02-15 | 2019-02-14 | Modified viral capsids |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210107947A1 (https=) |
| EP (1) | EP3752521A1 (https=) |
| JP (2) | JP2021514207A (https=) |
| CN (1) | CN112105630A (https=) |
| AU (2) | AU2019220368B2 (https=) |
| BR (1) | BR112020016666A2 (https=) |
| CA (1) | CA3095660A1 (https=) |
| SG (1) | SG11202009854XA (https=) |
| WO (1) | WO2019158619A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023518809A (ja) * | 2020-03-20 | 2023-05-08 | ディグニティー ヘルス | アデノ随伴ウイルスの改変方法及び分離方法 |
| CN116390773A (zh) | 2020-08-06 | 2023-07-04 | 应用医学研究基金会 | 用于通过基因疗法治疗诸如阿尔茨海默病的Tau蛋白病的病毒颗粒 |
| KR20240095539A (ko) | 2021-10-08 | 2024-06-25 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 변이체 및 이의 사용 방법 |
| CN115894659B (zh) * | 2022-10-19 | 2023-11-10 | 上海优宁维生物科技股份有限公司 | 微管相关蛋白Tau抗原及其制备方法和应用 |
| WO2024191778A1 (en) | 2023-03-10 | 2024-09-19 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| AU2024332181A1 (en) | 2023-08-31 | 2026-02-12 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2025082618A1 (en) | 2023-10-20 | 2025-04-24 | Fuse Vectors Aps | In vitro parvovirus capsid manufacturing |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6368901A (en) * | 2000-05-31 | 2001-12-11 | Univ Saskatchewan | Modified bovine adenovirus having altered tropism |
| SI1496944T1 (sl) * | 2002-05-01 | 2009-02-28 | Univ Florida | Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov |
| WO2015048534A1 (en) * | 2013-09-26 | 2015-04-02 | University Of Florida Research Foundation, Inc. | Synthetic combinatorial aav capsid library for targeted gene therapy |
| WO2015117010A2 (en) * | 2014-01-31 | 2015-08-06 | Temple University Of The Commonwealth System Of Higher Education | Bag3 as a target for therapy of heart failure |
| EP3200830B1 (en) * | 2014-10-03 | 2020-09-09 | University of Massachusetts | High efficiency library-identified aav vectors |
| AU2016219789B2 (en) * | 2015-02-20 | 2021-03-25 | Fondazione Telethon | Methods and compositions for treating genetic eye diseases |
| US11866462B2 (en) * | 2016-05-04 | 2024-01-09 | Oregon Health & Science University | Recombinant adeno-associated viral vectors |
| AU2017302013B2 (en) * | 2016-07-29 | 2022-05-26 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| AU2017341849B2 (en) * | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| WO2018119330A2 (en) * | 2016-12-22 | 2018-06-28 | Oregon Health & Science University | Adeno associated viral vectors |
| EP3585883A4 (en) * | 2017-02-21 | 2021-04-14 | University of Florida Research Foundation, Incorporated | MODIFIED AAV CAPSID PROTEINS AND USES THEREOF |
| CA3053154A1 (en) * | 2017-06-30 | 2019-01-03 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsids and methods of use thereof |
-
2019
- 2019-02-14 SG SG11202009854XA patent/SG11202009854XA/en unknown
- 2019-02-14 US US16/970,004 patent/US20210107947A1/en not_active Abandoned
- 2019-02-14 JP JP2020566878A patent/JP2021514207A/ja active Pending
- 2019-02-14 CN CN201980026061.6A patent/CN112105630A/zh active Pending
- 2019-02-14 CA CA3095660A patent/CA3095660A1/en active Pending
- 2019-02-14 EP EP19703748.4A patent/EP3752521A1/en active Pending
- 2019-02-14 AU AU2019220368A patent/AU2019220368B2/en active Active
- 2019-02-14 WO PCT/EP2019/053610 patent/WO2019158619A1/en not_active Ceased
- 2019-02-14 BR BR112020016666-9A patent/BR112020016666A2/pt unknown
-
2024
- 2024-02-02 JP JP2024014824A patent/JP2024050766A/ja active Pending
- 2024-07-01 AU AU2024204557A patent/AU2024204557A1/en active Pending
- 2024-08-13 US US18/802,552 patent/US20250051396A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020016666A2 (pt) | 2020-12-15 |
| US20210107947A1 (en) | 2021-04-15 |
| JP2021514207A (ja) | 2021-06-10 |
| SG11202009854XA (en) | 2020-11-27 |
| WO2019158619A1 (en) | 2019-08-22 |
| AU2019220368A1 (en) | 2020-10-08 |
| AU2019220368B2 (en) | 2024-06-13 |
| AU2024204557A1 (en) | 2024-07-25 |
| EP3752521A1 (en) | 2020-12-23 |
| CN112105630A (zh) | 2020-12-18 |
| US20250051396A1 (en) | 2025-02-13 |
| JP2024050766A (ja) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250051396A1 (en) | Modified viral capsids | |
| El Andari et al. | Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders | |
| US11117933B2 (en) | Selective recovery | |
| CN108699565B (zh) | 用于定向腺相关病毒(aav)的靶向肽 | |
| KR102649543B1 (ko) | 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도 | |
| Hamann et al. | Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors | |
| CN116209768A (zh) | 用于通过高变区交换工程化新杂合aav衣壳的方法 | |
| US20220372512A1 (en) | Methods and aav vectors for in vivo transduction | |
| CN111718418B (zh) | 一种增强基因编辑的融合蛋白及其应用 | |
| JP2026509271A (ja) | カプシドポリペプチドおよびその使用方法 | |
| CN111718420A (zh) | 一种用于基因治疗的融合蛋白及其应用 | |
| WO2023184107A1 (en) | Crispr-cas13 system for treating mecp2-associated diseases | |
| TW202325720A (zh) | 經修飾aav蛋白殼及載體 | |
| Davidsson et al. | Barcoded Rational AAV Vector Evolution enables systematic in vivo mapping of peptide binding motifs | |
| Dai et al. | Discovering human cell‐compatible gene therapy virus variants via optimized screening in mouse models | |
| CN121358754A (zh) | 具有外周器官去靶向性的新型嗜神经性腺相关病毒衣壳 | |
| JP2024517957A (ja) | ベクター系 | |
| Goertsen | Expanding adeno-associated viral capsid engineering to multiple variable regions for diversified tropism | |
| US12509490B2 (en) | AAV capsids for targeting nervous system and uses thereof | |
| WO2023184108A1 (en) | Crispr-cas13 system for treating ube3a-associated diseases | |
| WO2025185625A1 (zh) | 特异性靶向人组织的多肽序列及其在构建递送载体中的应用 | |
| Zdechlik | Engineering Adeno-Associated Virus for Receptor-Mediated Gene Delivery | |
| Herrmann | Dissection and optimization of Adeno-associated virus (AAV) DNA family shuffling technology: The journey is the reward | |
| WO2021237104A1 (en) | Methods and compositions to spread protein cargoes across multi-nucleated cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240131 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20241028 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241028 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250129 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250129 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250129 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250308 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250702 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251021 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251215 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251215 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251215 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260330 |